Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPILOT: Once-daily vs twice-daily inhaled colistimethate sodium in cystic fibrosis with chronic Pseudomonas aeruginosa lung infection
2022-000476-18Phase 3Active
- Sponsor
- EnBiotix
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colistimethate sodium in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection (2 arms), sponsored by EnBiotix. Primary endpoint: Number of observed safety events during the 28-day treatment period in each treatment arm. Started Mar 2022; status: active.
02
Drugs
colistimethate sodium
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2022-000476-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000476-18.